Stentless florence robotic intracorporeal neobladder (FloRIN), a feasibility prospective randomized clinical trial

• Published in: European journal of surgical oncology 2024-01, Vol.50 (1), p.107259-107259, Article 107259
• Main Authors: Lambertini, Luca, Di Maida, Fabrizio, Cadenar, Anna, Nardoni, Samuele, Grosso, Antonio Andrea, Valastro, Francesca, Spinelli, Pietro, Fantechi, Riccardo, Tuccio, Agostino, Vittori, Gianni, Mari, Andrea, Masieri, Lorenzo, Minervini, Andrea
• Format: Article
• Language: English
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2023.107259

Aim of the study was to evaluate perioperative, postoperative and mid-term functional outcomes of Florence intracorporeal neobladder (FloRIN) configuration technique performed with stentless procedure. This single institution randomized 1:1 prospective series included consecutive patients treated with Robot-Assisted Radical Cystectomy (RARC) and FloRIN reconfiguration from January 2021 to February 2022. Postoperative complications were graded according to Clavien Dindo classification and divided in early (30 days). Overall, 63 patients were included in the analysis. Among these 32 (50.8 %) were treated with RARC + stentless FloRIN while 31 (49.2 %) underwent stent placement procedure. No differences were found in terms of baseline characteristics between the two groups. Stentless procedure was associated with significant shorter console time 328 vs 374 min (p = 0.04) and lower estimated blood loss (EBL) 330 vs 350 ml (p = 0.04) comparing to stent group. As regards perioperative features, no significant differences were recorded in terms of canalization (p = 0.58) and time to drainage removal (p = 0.11) while a shorter length of hospital stay was found in case of stentless procedure (p = 0.04). Early postoperative complications Clavien ≥ 3a occurred in 9.3 % and 12.9 % of patients while delayed major complications were recorded in the 3.1 % and 9.6 % of patients treated with stentless and stent FloRIN, respectively (p = 0.09). As regards the mid-term functional outcomes, no differences were found in terms of kidney function loss in both 3rd and 6th month assessment (p = 0.13 and p = 0.14, respectively). In conclusion, Stentless FloRIN is a feasible and safe IntraCorporeal Neobladder technique, as confirmed by the worthy functional and perioperative outcomes achieved in comparison with the standard FloRIN ureteral management strategy.